ArticleMolecular and cellular biochemistry2026
L-carnitine mitigates urographin-induced nephrotoxicity via modulation of inflammatory, oxidative, and apoptotic pathways in rat kidney.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Contrast-induced nephropathy (CIN) remains a significant clinical challenge, particularly following the administration of iodinated agents such as urographin. L-carnitine (LC) is a substance known for its anti-inflammatory and antiapoptotic effects. This study investigates the nephroprotective potential of LC through its regulatory effects on inflammation, oxidative stress, and apoptosis in a rat model of CIN. Thirty-two Wistar albino rats were assigned to four groups: Control, urographin (URO, 10 mL/kg i.p.), URO-LC (200 mg/kg L-carnitine i.p. for 10 days), and LC alone. Renal function markers (urea, creatinine), oxidative stress indicators as total oxidans status (TOS), total antioxidant status (TAS), oxidative stress (OSI), and histopathological features were evaluated. The immunohistochemical expression of tumor necrosis factor alpha (TNF-α) and Caspase-3 (Cas-3), along with the mRNA expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and Caspase-9 (Cas-9), were assessed. URO significantly increased serum urea and creatinine levels, TOS and OSI values. TNF-α and Cas-3 immunoreactivity, along with Bax and Cas-9 gene expression, were markedly elevated in the URO group, while anti-apoptotic Bcl-2 expression was suppressed. URO also induced severe histological damage. LC treatment reversed these effects, preserving tissue integrity and restoring molecular markers toward baseline levels. LC exerts potent nephroprotective effects against URO-induced renal injury by attenuating oxidative stress, suppressing pro-inflammatory and apoptotic signaling, and promoting anti-apoptotic gene expression. These findings support its potential clinical use in the prevention of contrast-induced renal damage.
Indexed as
Identifiers
41261345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.